In HER2-positive breast cancer, the co-administration of lapatinib with capecitabine has been found to extend median progression-free survival compared to the administration of capecitabine alone following trastuzumab-based therapy (8.4 months vs. 4.4 months; hazard ratio 0.49; p < 0.001). This evidence concerns the gene ERBB2 and breast cancer.